RESUMO
The "Euro-Lupus Cohort" is composed by 1000 patients with systemic lupus erythematosus (SLE) that have been followed prospectively since 1991. These patients have been gathered by a European consortium--the "Euro-Lupus Project Group". This consortium was originated as part of the network promoted by the "European Working Party on SLE", a working group created in 1990 in order to promote research in Europe on the different problems related to this disease. The "Euro-Lupus Cohort" provides an updated information on the SLE morbidity and mortality characteristics in the present decade as well as defines several clinical and immunological prognostic factors.
Assuntos
Doenças Autoimunes/diagnóstico , Doenças Autoimunes/epidemiologia , Lúpus Eritematoso Sistêmico/diagnóstico , Lúpus Eritematoso Sistêmico/epidemiologia , Idade de Início , Anticorpos Antinucleares/sangue , Doenças Autoimunes/sangue , Doenças Autoimunes/mortalidade , Estudos de Coortes , Europa (Continente)/epidemiologia , Feminino , Seguimentos , Humanos , Lúpus Eritematoso Sistêmico/sangue , Lúpus Eritematoso Sistêmico/mortalidade , Masculino , Morbidade , Prognóstico , Estudos Prospectivos , Taxa de SobrevidaAssuntos
Adenocarcinoma Mucinoso/diagnóstico , Adenocarcinoma/diagnóstico , Tamponamento Cardíaco/etiologia , Neoplasias Cardíacas/diagnóstico , Adenocarcinoma/complicações , Adenocarcinoma Mucinoso/complicações , Adulto , Neoplasias Cardíacas/complicações , Humanos , Metástase Linfática , Masculino , PericárdioRESUMO
We present a patient with severe idiopathic pure red cell aplasia who responded spectacularly to cyclosporin after failure of corticoid treatment and cyclophosphamide. We conclude that cyclosporin should be considered a viable therapeutic alternative to cytotoxic immunosuppressive treatments in this disease.
Assuntos
Ciclosporinas/uso terapêutico , Aplasia Pura de Série Vermelha/tratamento farmacológico , Adulto , Feminino , HumanosAssuntos
Anticonvulsivantes/efeitos adversos , Carbamazepina/análogos & derivados , Hiponatremia/induzido quimicamente , Idoso , Anticonvulsivantes/uso terapêutico , Carbamazepina/efeitos adversos , Carbamazepina/uso terapêutico , Epilepsia/tratamento farmacológico , Humanos , Masculino , OxcarbazepinaRESUMO
Temporal arteritis (TA) is a vasculitis involving mainly cranial branches of the aorta that can lead to ischemic complications such as amaurosis or ischemic stroke. Increment in the platelet count has been described in the acute period of the disease. We studied retrospectively the platelet count in patients with TA, its association with ischemic complications and quantified its response to therapy. We found thrombocytosis in 44% of 34 patients with TA, with a mean reduction in the platelet count of 25.1% after therapy. We were also able to quantify the increment in the platelet count at the onset of the disease and its response to prednisone in a group of 5 patients. We did not find any relation between platelet count and ischemic complications of the disease or the result of the temporal artery biopsy. In conclusion TA is associated with an increase in the platelet count, with a 25% reduction after prednisone therapy. These two determinations are not related to ischemic complications of the disease.